Immuneering Corp Stock Price, News & Analysis

Immuneering (Nasdaq: IMRX) said it completed End-of-Phase 2 interactions with the FDA and received scientific advice from the EMA, achieving alignment on its planned global Phase 3 registrational trial MAPKeeper 301 for atebimetinib (320 mg QD) + mGnP in first-line metastatic pancreatic ductal adenocarcinoma.

The company plans to enroll ~510 patients, use overall survival as the primary endpoint, expects to dose the first patient in mid-2026, and plans to report topline results in mid-2028. Management reiterated that current cash and equivalents are expected to fund operations into 2029. An overall survival update from the Phase 2a trial is planned in the coming weeks.

Immuneering (Nasdaq: IMRX) announced it is expected to be added to the Nasdaq Biotechnology Index (NBI). The addition is scheduled to become effective prior to market open on Monday, December 22, 2025.

The NBI tracks securities classified as biotechnology or pharmaceutical under the Industry Classification Benchmark and is evaluated annually each December. Index membership requires meeting eligibility criteria such as minimum market capitalization, average daily trading volume, and public company seasoning. The NBI is calculated using a modified capitalization-weighted methodology.

Immuneering (Nasdaq: IMRX) announced management will present at the Piper Sandler 37th Annual Healthcare Conference in New York City.

Presenters include Ben Zeskind (CEO), Igor Matushansky M.D. (CMO), Harold “E.B.” Brakewood (CBO) and Mallory Morales, CPA (CAO, Treasurer). Format: company presentation and 1x1 investor meetings. Presentation time: December 4, 11:10–11:30 a.m. ET, Staten Island Track (Kennedy 1, 4th Floor). The presentation will be webcast live and archived in the Investor Relations section under Events & Presentations.

Immuneering (NASDAQ: IMRX) reported Q3 2025 results and clinical updates on November 12, 2025. Key clinical news: an 86% overall survival at 9 months in 34 first-line pancreatic cancer patients treated with atebimetinib + mGnP (median follow-up 9 months), favorable tolerability with Grade 3 neutropenia and anemia as the only categories >10%, and new case studies including a complete response and a patient converted to surgery with curative intent after atebimetinib + FOLFIRINOX.

Corporate and financial highlights: raised approximately $225 million in financings (including a $25M private placement with Sanofi), cash of $227.6M at Sept 30, 2025 with runway into 2029, and a U.S. composition-of-matter patent for atebimetinib expected to expire in Aug 2042.

Immuneering (Nasdaq: IMRX) will report third quarter 2025 financial results and share new clinical case studies on Wednesday, November 12, 2025, after market close.

Trial investigators will present case studies from first-line pancreatic cancer patients treated with atebimetinib plus FOLFIRINOX in the company’s Phase 2a study. A conference call and webcast are scheduled for 1:30 pm PT / 4:30 pm ET on November 12, 2025.

Live access via webcast or by dialing the listed U.S. and international numbers (conference ID 7742025). A replay will be available from the Investors section of the company website for one year; registration via the Events webcast link is required.

Immuneering (Nasdaq: IMRX) announced a conference call and webcast scheduled for September 29, 2025, at 8:30 am ET to discuss recently released overall survival and safety data from their Phase 2a clinical trial. The trial evaluated atebimetinib + mGnP in 34 first-line pancreatic cancer patients with 9 months median follow-up.

The data will also be featured in a poster presentation at the PanCAN Scientific Summit 2025 on September 28. Interested parties can access the conference call via webcast or by dialing (800) 715-9871 (U.S.) or (646) 307-1963 (international) with conference ID 9502940.

Immuneering (Nasdaq: IMRX), a clinical-stage oncology company, has announced the pricing of a significant $175 million public offering of Class A common stock at $9.23 per share, consisting of 18,959,914 shares. The company has also granted underwriters a 30-day option to purchase up to 2,843,987 additional shares.

Concurrent with the public offering, Sanofi has agreed to make a $25 million private placement investment, purchasing 2,708,559 shares at the same price per share. Both transactions are expected to close around September 26, 2025. The proceeds will be used to advance Immuneering's preclinical and clinical development programs and for general corporate purposes.

Immuneering (Nasdaq: IMRX), a clinical-stage oncology company, has announced a proposed underwritten public offering of its Class A common stock and pre-funded warrants. The company will grant underwriters a 30-day option to purchase up to 15% additional Class A common stock shares.

Simultaneously, Sanofi has agreed to invest $25.0 million in a concurrent private placement, purchasing either Class A or non-voting Class B common stock at the same price as the public offering. Leerink Partners and Oppenheimer & Co. Inc. are serving as joint bookrunners for the offering and placement agents for the private placement.

The proceeds will be used to advance Immuneering's preclinical and clinical product development and for general corporate purposes. The offering is subject to market conditions, and the private placement is contingent upon the offering's closing.

Immuneering (Nasdaq: IMRX) reported exceptional clinical trial results for atebimetinib combined with mGnP in first-line pancreatic cancer treatment. The Phase 2a trial (N=34) demonstrated remarkable 86% overall survival (OS) at 9 months, significantly outperforming the standard of care benchmark of ~47%. The study also showed 53% progression-free survival (PFS) at 9 months, compared to the standard ~29%.

The drug maintained a favorable tolerability profile, with only two Grade 3 adverse events occurring in more than 10% of patients. Atebimetinib, a Deep Cyclic Inhibitor targeting MEK, represents a novel approach in targeted therapy by pulsing faster than tumors can adapt. The company expects regulatory feedback on pivotal trial plans in Q4 2025 and aims to initiate a Phase 3 trial by year-end.